Alzinova AB (SE:ALZ)
:ALZ
Top Page
Alzinova AB
(ALZ)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.75
▼(-8.66% Downside)
Action:ReiteratedDate:01/13/26
The score is primarily weighed down by weak financial performance (large ongoing losses and heavy cash burn implying continued financing/dilution risk) and bearish technicals (price below major moving averages with negative MACD). Low leverage and sizable equity provide some solvency support, but valuation metrics are not constructive given negative earnings and no dividend data.
Positive Factors
Conservative balance sheet
Very low leverage and a large equity base materially reduce near-term refinancing risk and give management flexibility to pursue clinical programs and partner negotiations over the next several quarters, improving solvency resilience despite operating losses.
Negative Factors
High and persistent cash burn
Large negative operating and free cash flows are structural for an early biotech but imply ongoing dependence on external financing. Persistent burn increases dilution risk, constrains strategic optionality, and pressures timelines for partnerships or capital raises over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a large equity base materially reduce near-term refinancing risk and give management flexibility to pursue clinical programs and partner negotiations over the next several quarters, improving solvency resilience despite operating losses.
Read all positive factors
Alzinova AB (ALZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr90.94M
Dividend YieldN/A
Average Volume (3M)655.64K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth-67.00%
EPS Growth13.62%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding154,398,900
10 Day Avg. Volume664,473
30 Day Avg. Volume655,642
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)1.87
Price to Sales (P/S)7703.54
P/FCF Ratio-6.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Alzinova AB Business Overview & Revenue Model
Company Description
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease...
How the Company Makes Money
Alzinova AB generates revenue primarily through the advancement of its drug candidates, including potential milestone payments from partnerships and collaborations with larger pharmaceutical companies. The company may also earn revenue from licens...
Alzinova AB Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.00K | 30.00K | 270.00K | 16.63M | 17.32M | 14.90M |
| Gross Profit | 26.01M | 16.81M | 19.87M | 33.27M | 34.64M | 29.80M |
| EBITDA | -26.64M | -20.32M | 42.00K | -13.07M | -7.52M | -6.50M |
| Net Income | -26.88M | -20.55M | -16.48M | -13.07M | -7.58M | -6.50M |
Balance Sheet | ||||||
| Total Assets | 136.90M | 133.23M | 123.19M | 111.62M | 91.69M | 100.82M |
| Cash, Cash Equivalents and Short-Term Investments | 485.00K | 15.50M | 22.03M | 32.04M | 28.84M | 55.98M |
| Total Debt | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Total Liabilities | 9.05M | 9.40M | 9.33M | 6.09M | 3.22M | 4.79M |
| Stockholders Equity | 127.85M | 123.82M | 113.86M | 105.53M | 88.47M | 96.02M |
Cash Flow | ||||||
| Free Cash Flow | -39.60M | -37.05M | -34.82M | -26.95M | -27.14M | -21.17M |
| Operating Cash Flow | -25.68M | -20.27M | -15.21M | -10.31M | -9.82M | -6.27M |
| Investing Cash Flow | -25.91M | -16.78M | -19.60M | -16.63M | -17.32M | -14.90M |
| Financing Cash Flow | 24.40M | 30.52M | 24.80M | 30.15M | 0.00 | 43.41M |
Alzinova AB Technical Analysis
Negative
0.82
Price Trends
0.70
Negative
1.04
Negative
1.27
Negative
Market Momentum
-0.03
Positive
43.36
Neutral
6.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZ, the sentiment is Negative. The current price of 0.82 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.70, and below the 200-day MA of 1.27, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.36 is Neutral, neither overbought nor oversold. The STOCH value of 6.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZ.
Alzinova AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr105.70M | -1.81 | -72.82% | ― | 40.91% | 57.92% | |
44 Neutral | kr144.37M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr39.16M | -1.03 | -457.91% | ― | ― | -19.35% | |
42 Neutral | kr90.94M | -4.20 | -21.31% | ― | -67.00% | 13.62% | |
42 Neutral | kr85.48M | -1.86 | -120.13% | ― | ― | 49.09% | |
42 Neutral | kr103.08M | -1.34 | -294.38% | ― | 186.74% | 73.17% |
* Healthcare Sector Average
SE:ALZ
Alzinova AB
0.59
-1.99
-77.17%
SE:BIOSGN
Biosergen AB
36.40
1.80
5.20%
SE:NICA
Nanologica AB
0.35
-1.16
-76.76%
SE:BIOVIC.B
Biovica International AB Class B
0.37
-0.54
-59.78%
SE:MODTX
Modus Therapeutics Holding AB
0.32
-0.17
-34.55%
SE:NXTCL
NextCell Pharma AB
1.30
-1.74
-57.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.